Eli Lilly's (LLY) Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1182.62 +3.35 (0.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1179.27 | 52 Week High | $88.16 | |||
| Open | $1181.24 | 52 Week Low | $67.88 | |||
| Day High | $1188.70 | P/E | 273.75 | |||
| Day Low | $1172.81 | EPS | $4.32 | |||
| Volume | 1,244,234 | |||||
